Gastrointestinal pH profiles in patients with inflammatory bowel disease
- 1 July 1998
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 12 (7), 673-678
- https://doi.org/10.1046/j.1365-2036.1998.00358.x
Abstract
5-Amino salicylic acid preparations are used in therapy for patients with inflammatory bowel diseases. The bioavailability of these drugs depends on their coating. To determine whether intraluminal pH is decreased by the presence of inflammation, thereby altering the release of 5-amino salicylic acid in the intestinal lumen. Intraluminal gastrointestinal pH was measured by means of a radiotelemetry capsule in 12 healthy controls, in 12 patients with Crohn’s disease (five with active disease), and in 11 patients with ulcerative colitis (seven with active disease). The median gastric pH values in the patient groups (Crohn’s disease 2.4, range 1.5–4.1; ulcerative colitis 1.95, range 1.55–4.4) were significantly higher than those observed in the controls (1.55, range 0.95–2.6). In the small bowel and colonic segments, all the pH values of Crohn’s disease patients were comparable to those of the controls, as were the pH values in the proximal small intestine and in the left colon in patients with ulcerative colitis. However, the latter group had higher pH values in the terminal ileum, the caecum and the right colon. Patients with active disease had comparable median gastrointestinal pH values to patients in remission. The luminal release of 5-amino salicylic acid might not be inhibited by low pH in patients with active inflammatory bowel diseases. This supports a safe disintegration of the slow release mesalazine preparations even in the presence of severe disease.Keywords
This publication has 13 references indexed in Scilit:
- Nutrition support in inflammatory bowel diseaseMedical Clinics of North America, 1994
- Very low intraluminal colonic pH in patients with active ulcerative colitisDigestive Diseases and Sciences, 1993
- Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trialGastroenterology, 1993
- Sulfasalazine RevisitedAnnals of Internal Medicine, 1993
- Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled studyGastroenterology, 1993
- Postoperative Recurrence of Crohn’s Disease in Relation to Radicality of Operation and Sulfasalazine Prophylaxis: A Multicenter TrialDigestion, 1989
- Fecal Lactate and Ulcerative ColitisGastroenterology, 1988
- Organic anions and the diarrhea of inflammatory bowel diseaseDigestive Diseases and Sciences, 1988
- Measurement of gastrointestinal pH profiles in normal ambulant human subjects.Gut, 1988
- Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease.Gut, 1986